Repligen Corporation
RGEN

$8.09 B
Marketcap
$144.46
Share price
Country
$-2.08
Change (1 day)
$211.13
Year High
$113.50
Year Low

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

marketcap

P/E ratio for Repligen Corporation (RGEN)

P/E ratio as of 2023: 240.96

According to Repligen Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 240.96. At the end of 2022 the company had a P/E ratio of 50.49.

P/E ratio history for Repligen Corporation from 1986 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 240.96
2022 50.49
2021 113.57
2020 168.06
2019 208.85
2018 138.91
2017 48.92
2016 88.58
2015 99.54
2014 78.76
2013 26.84
2012 13.71
2011 -2645.99
2010 -30.72
2009 25.81
2008 4.01
2007 -107.95
2006 159.95
2005 -17.13
2004 -9.42
2003 -27.60
2002 -23.35
2001 -14.46
2000 -54.32
1999 -22.07
1998 -24.49
1997 -48.96
1996 -1.50
1995 -0.81
1994 -3.27
1993 -7.53
1992 -13.82
1991 -23.02
1990 -37.10
1989 -17.39
1988 218.94
1987 -4.53
1986 -24.08